As GLP-1 receptor agonists reshape the treatment of diabetes and obesity for millions, a large systematic study now places a quieter cost on the scales: a meaningfully elevated risk of hair loss compared to alternative medications. Researchers at the University of Pennsylvania, analyzing records from more than 39,000 patients, found that those on GLP-1 drugs shed hair at rates 37 to 68 percent higher than peers on other diabetes therapies — a finding that transforms years of patient whispers into documented evidence. The absolute numbers remain modest, but the relative signal is strong enough
GLP-1 drugs linked to 37-68% higher hair loss risk in diabetes patients
Patients using GLP-1 drugs may experience hair loss, potentially affecting quality of life and treatment adherence decisions.